APP and Alzheimer disease: The initial target for the first GSI, however, was Alzheimer’s disease (AD), in which the γ-secretase complex is associated with the deposition of senile plaques, resulting from the aberrant deposition of amyloid precursor protein (APP) and the production of short amyloid-β peptides (Aβ) [112].